Answers are grounded in this paper and cite their sources.
Patient-derived organoids (PDOs) provide experimentally tractable models of non-small cell lung cancer (NSCLC), but their use is limited by variable establishment efficiency, overgrowth by normal airway epithelium, and incompletely standardized culture conditions. We developed an optimized, subtype-adapted NSCLC PDO culture system based on conditioned medium from irradiated Swiss 3T3-J2 fibroblasts (iJ2-CM), combined with the ROCK inhibitor Y-27632 and the TGF-β receptor inhibitor A83-01. Systematic cytokine screening identified insulin-like growth factor-1 (IGF-1) and epidermal growth factor (EGF) as potent enhancers of the proliferation and viability of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) organoids, respectively. Matched histology and whole-exome sequencing demonstrated retention of lineage-associated features and tumor-associated genomic alterations. Importantly, this platform supports multiple downstream applications, including scalable drug screening and autologous immune cell co-culture assays, enabling the prediction of patient-specific responses to chemotherapy, targeted therapies, and immunotherapies. Collectively, this study establishes a physiologically relevant, subtype-tailored, and experimentally scalable NSCLC organoid platform with potential for mechanistic investigation, precision drug testing, and translational cancer research.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: